ANAPTYSBIO, INC. Payments of Debt Issuance Costs
ANAPTYSBIO, INC. (ANAB) reported Payments of Debt Issuance Costs of $0 for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2025-11-04
- ANAPTYSBIO, INC. payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments of debt issuance costs for the quarter ending 2024-09-30 was $67.00K.
- ANAPTYSBIO, INC. payments of debt issuance costs for the quarter ending 2024-06-30 was $36.00K.
- ANAPTYSBIO, INC. payments of debt issuance costs for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. payments of debt issuance costs for fiscal 2018 was $0.00.
- ANAPTYSBIO, INC. payments of debt issuance costs for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- ANAPTYSBIO, INC. payments of debt issuance costs for fiscal 2016 was $255.00K.
- ANAPTYSBIO, INC. payments of debt issuance costs for fiscal 2015 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-09-30 | $67.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $103.00K derived: sum of 2 quarters · filed 2025-11-04 | $103.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $36.00K 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $0.00 derived: sum of 2 quarters · filed 2024-11-05 | $43.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $43.00K 10-Q · filed 2024-08-05 | ||
| 2023-03-31 | $43.00K 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $288.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $288.00K derived: sum of 2 quarters · filed 2023-11-02 | $290.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $2.00K 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $2.00K 10-Q · filed 2023-05-11 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $0.00 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $0.00 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-04 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 | |||
| 2016-12-31 | $255.00K 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |